Karen A. Dawes, Director at REPLIGEN CORP (RGEN), sold 275 shares at $161.00 ($44K) on 2025-12-17, disclosed to the SEC on 2025-12-18.
Open-market sale of $44k RGEN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| RGEN | SELL | 2022-09-09 | $352K | — | Filing → |
| RGEN | SELL | 2022-05-26 | $4.4M | — | Filing → |
| RGEN | SELL | 2021-11-12 | $2.5M | — | Filing → |